Abbott Goes After Mylan Over Simcor ANDA

Law360, New York (June 29, 2010, 1:09 PM EDT) -- Abbott Laboratories has filed a patent infringement suit in an effort to stop Mylan Inc. from making a generic version of Simcor, a cholesterol treatment that includes Niaspan, another Abbott drug mired in litigation.

Abbott filed suit Monday in the U.S. District Court for the District of Delaware, where it has cases pending against five other generics makers over their attempts to introduce their own versions of Simcor or Niaspan.

According to the suit, Mylan submitted an abbreviated new drug application with the U.S. Food and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.